AcelRx Pharmaceuticals, Inc. (ACRX) Position Reduced by Vanguard Group Inc.

Vanguard Group Inc. lessened its holdings in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) by 11.8% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,357,461 shares of the specialty pharmaceutical company’s stock after selling 182,074 shares during the period. Vanguard Group Inc. owned about 2.99% of AcelRx Pharmaceuticals worth $2,918,000 at the end of the most recent reporting period.

Separately, LMR Partners LLP bought a new stake in AcelRx Pharmaceuticals during the 2nd quarter worth approximately $319,000. Institutional investors and hedge funds own 13.94% of the company’s stock.

Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ ACRX) opened at $2.20 on Wednesday. AcelRx Pharmaceuticals, Inc. has a one year low of $1.55 and a one year high of $5.75. The company has a debt-to-equity ratio of -0.43, a current ratio of 4.78 and a quick ratio of 4.71.

In related news, Director Mark G. Edwards acquired 30,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was acquired at an average cost of $1.90 per share, with a total value of $57,000.00. Following the acquisition, the director now directly owns 150,000 shares in the company, valued at approximately $285,000. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Lawrence G. Hamel sold 10,161 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $5.29, for a total transaction of $53,751.69. Following the sale, the insider now directly owns 16,379 shares of the company’s stock, valued at $86,644.91. The disclosure for this sale can be found here. In the last 90 days, insiders have acquired 42,000 shares of company stock worth $89,380. 28.10% of the stock is owned by company insiders.

A number of equities research analysts have commented on the stock. ValuEngine cut shares of AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 12th. Jefferies Group cut shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 13th. Royal Bank Of Canada decreased their target price on shares of AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, October 13th. Roth Capital set a $8.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, October 12th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, October 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. AcelRx Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $6.83.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/12/06/acelrx-pharmaceuticals-inc-acrx-position-reduced-by-vanguard-group-inc.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Institutional Ownership by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply